Aldeyra Therapeutics Inc ALDX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.63 up $0.02, 2.89% at close Nov 6
Last close · Previous close $0.62
- Market cap
- $38.23MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.31Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.63up $0.02, 2.89%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.62Nov 5
- Volume547.16KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume981.77KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.53 to $5.93; now $0.63
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ALDX trailed the S&P 500 in all 7 periods.
| Period | ALDX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ALDX: down 30.8% S&P 500: down 5.6% | ALDX trailed the S&P 500 by 25.2 percentage points Trailed |
| 3M | ALDX: down 60.1% S&P 500: down 4.1% | ALDX trailed the S&P 500 by 56.0 percentage points Trailed |
| YTD | ALDX: down 87.8% S&P 500: up 8.7% | ALDX trailed the S&P 500 by 96.5 percentage points Trailed |
| 1Y | ALDX: down 86.8% S&P 500: up 10.9% | ALDX trailed the S&P 500 by 97.7 percentage points Trailed |
| Long term | ||
| 3Y | ALDX: down 71.8% S&P 500: up 75.0% −34.5% vs +20.5% a year | ALDX trailed the S&P 500 by 146.8 percentage points Trailed |
| 5Y | ALDX: down 92.9% S&P 500: up 67.8% −41.1% vs +10.9% a year | ALDX trailed the S&P 500 by 160.7 percentage points Trailed |
| 10Y | ALDX: down 88.0% S&P 500: up 313.1% −19.1% vs +15.2% a year | ALDX trailed the S&P 500 by 401.1 percentage points Trailed |
$10,000 invested in ALDX 10 years ago (Nov 4, 2016) would be worth about $1,196 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ALDX trailed the S&P 500 in all 7 periods.
| Period | ALDX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ALDX: down 30.8% S&P 500: down 5.6% | ALDX trailed the S&P 500 by 25.2 percentage points Trailed |
| 3M | ALDX: down 60.1% S&P 500: down 4.3% | ALDX trailed the S&P 500 by 55.8 percentage points Trailed |
| YTD | ALDX: down 87.8% S&P 500: up 7.8% | ALDX trailed the S&P 500 by 95.6 percentage points Trailed |
| 1Y | ALDX: down 86.8% S&P 500: up 9.7% | ALDX trailed the S&P 500 by 96.5 percentage points Trailed |
| Long term | ||
| 3Y | ALDX: down 71.8% S&P 500: up 68.8% −34.5% vs +19.1% a year | ALDX trailed the S&P 500 by 140.6 percentage points Trailed |
| 5Y | ALDX: down 92.9% S&P 500: up 56.9% −41.1% vs +9.4% a year | ALDX trailed the S&P 500 by 149.8 percentage points Trailed |
| 10Y | ALDX: down 88.0% S&P 500: up 252.6% −19.1% vs +13.4% a year | ALDX trailed the S&P 500 by 340.6 percentage points Trailed |
$10,000 invested in ALDX 10 years ago (Nov 4, 2016) would be worth about $1,196 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$14.85
Closing high on . Now 95.7% below that record.
Split-adjusted daily closes since May 2, 2014.
Stock splits
ALDX hasn’t split since its price history begins in 2014.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.31 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 1.1×Book value as of Sep 30, 2026
Price relative to accounting equity (book value) per share on the Sep 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −50.08%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$2.29MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ALDX DCF in Excel. Value Aldeyra Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$19.13M
- Diluted EPS
- −$0.31
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$15.81M | −$0.27 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$9.93M | −$0.17 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$9.77M | −$0.16 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$7.69M | −$0.13 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$6.46M | −$0.10 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$3.45M | −$0.06 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$5.45M | −$0.09 |
| Q3 FY26 (Sep 30, 2026) | $0.00 | −$3.76M | −$0.06 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$57.78M | −$1.07 |
| FY22 (Dec 31, 2022) | $0.00 | −$62.02M | −$1.06 |
| FY23 (Dec 31, 2023) | $0.00 | −$37.54M | −$0.64 |
| FY24 (Dec 31, 2024) | $0.00 | −$55.85M | −$0.94 |
| FY25 (Dec 31, 2025) | $0.00 | −$33.85M | −$0.56 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$19.15MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$19.12MLast 12 months
- Capital spending$23.10KLast 12 months
Shareholder returns
- $80.83KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $40.97MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$458.70KAs of Sep 30, 2026
- Net cash$40.52MAs of Sep 30, 2026
- 5.45As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −48.0%Last 12 months
Over the last 12 months, Aldeyra Therapeutics lost money: its net loss was 48.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −33.3%Last 12 months
Over the last 12 months, Aldeyra Therapeutics’s net loss was 33.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Aldeyra Therapeutics Inc
A securities class action was filed in the United States District Court for the District of Massachusetts alleging that Aldeyra and certain officers made materially false and misleading statements about the efficacy and reliability of reproxalap clinical trials. The FDA's March 2026 Complete Response Letter stated that the "inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings" and that the application "failed to demonstrate efficacy." "The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome. In the Aldeyra action, investors who purchased shares based on repeated claims of consistent clinical trial results now face a 70.7% loss following the FDA's findings." — Joseph E. Levi, Esq. Post-Deadline Procedures After May 29, 2026, the court will review competing motions and appoint a lead plaintiff. Absent class members need take no action at this stage and will receive notice of any proposed settlement. Find out if you qualify to recover losses or call Joseph E. Levi, Esq. at (212) 363-7500. Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com Frequently Asked Questions About the ALDX Lawsuit Q: What is the ALDX lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is May 29, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date. Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run. Q: How do I know if I lost enough money to be the lead plaintiff? A: There is no minimum loss threshold. Courts appoint the investor with the largest provable loss who is willing and able to represent the class adequately. Contact Levi & Korsinsky before May 29, 2026 to evaluate. Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs. Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery. Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (888) SueWallSt Fax: (212) 363-7171 SOURCE SueWallSt.com
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ALDX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ALDX stock FAQ
What is ALDX stock’s price today?
Aldeyra Therapeutics (ALDX) traded at $0.63 at the close on , up $0.02 (2.89%) from the previous close of $0.62. Over the past 52 weeks it has traded between $0.53 and $5.93.
If you invested $1,000 in ALDX 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ALDX on would be worth about $120 at the close on , a total return of −88.0%. The same $1,000 would be worth $71 if invested five years ago and $132 if invested one year ago. Past performance doesn’t predict future returns.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market capitalization is about $38.2 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.63 (how market cap works). Aldeyra Therapeutics reported 60.33M shares outstanding at the end of its latest quarter ().
What is ALDX’s P/E ratio?
ALDX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.31).
What are ALDX’s earnings per share?
ALDX’s diluted earnings per share were −$0.31 over the four quarters to , compared with −$0.73 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.06 per share, against −$0.13 a year earlier (how EPS works).
Does ALDX pay a dividend?
Aldeyra Therapeutics hasn’t paid a dividend in the last twelve months.
What is ALDX’s 52-week high and low?
Over the past 52 weeks ALDX has traded as low as $0.53 and as high as $5.93. At $0.63 at the close on , it is 89.3% below that high and 20.2% above the low.
What is ALDX’s all-time high?
ALDX’s highest closing price was $14.85 on , adjusted for stock splits. At $0.63 at the close on , it is 95.7% below that record.
Has ALDX stock ever split?
No. ALDX hasn’t split since its price history begins in 2014.
How has ALDX stock performed?
Including dividends and measured to the close on , ALDX has returned −87.8% so far this year and −86.8% over the past year, and −92.9% over five years (−41.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Aldeyra Therapeutics in?
Aldeyra Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does ALDX trade on?
Aldeyra Therapeutics trades on the Nasdaq under the ticker symbol ALDX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.